Development of novel vaccine candidates and challenge models for Plasmodium vivax
Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile efficacy. We started to develo...
Príomhchruthaitheoirí: | Alves, E, Salman, A, Janse, C, Khan, S, Hill, A, Reyes-Sandoval, A |
---|---|
Formáid: | Journal article |
Foilsithe / Cruthaithe: |
BioMed Central
2014
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
de réir: Alves, E, et al.
Foilsithe / Cruthaithe: (2017) -
A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
de réir: Alba Marina Gimenez, et al.
Foilsithe / Cruthaithe: (2021-09-01) -
Plasmodium vivax malaria vaccines: why are we where we are?
de réir: Reyes-Sandoval, A, et al.
Foilsithe / Cruthaithe: (2013) -
The challenges of Plasmodium vivax human malaria infection models for vaccine development
de réir: Roobsoong, W, et al.
Foilsithe / Cruthaithe: (2023) -
Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models
de réir: Salman, A, et al.
Foilsithe / Cruthaithe: (2017)